Page last updated: 2024-11-13

cibinetide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cibinetide: a synthetic 11-mer peptide that binds the tissue-protective receptor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91810664
CHEMBL ID3545305
MeSH IDM0578843

Synonyms (34)

Synonym
gtpl9677
cibinetide
ph-bsp
phbsp peptide
9w5677jkda ,
l-pyroglutamyl-l-glutamyl-l-glutaminyl-l-leucyl-l-glutamyl-l-arginyl-l-alanyl-l-leucyl-l-asparaginyl-l-seryl-l-serine
ara-290
ara290
pglu-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser
ara 290
phbsp
pyroglutamate-glutamyl-glutaminyl-leucyl-glutamyl-arginyl-alanyl-leucyl-asparagyl-seryl-serine
unii-9w5677jkda
cibinetide [usan]
l-serine, 5-oxo-l-prolyl-l-alpha-glutamyl-l-glutaminyl-l-leucyl-l-alpha-glutamyl-l-arginyl-l-alanyl-l-leucyl-l-asparaginyl-l-seryl-
l-pyroglutamyl-l-glutamyl-l-glutaminyl-l-ieucyl-l-glutamyl-l-arginyl-l-alanyl-l-leucyl-l-asparaginyl-l-seryl-l-serine
pyroglutamate helix b surface peptide
pyr-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser-oh
1208243-50-8
l-serine, 5-oxo-l-prolyl-l-.alpha.-glutamyl-l-glutaminyl-l-leucyl-l-.alpha.-glutamyl-l-arginyl-l-alanyl-l-leucyl-l-asparaginyl-l-seryl-
l-pyr-l-glu-l-gln-l-leu-l-glu-l-arg-l-ala-l-leu-l-asn-l-ser-l-ser
cibinetide [who-dd]
cibinetide [inn]
CHEMBL3545305
DB13006
cibinetide (usan/inn)
D11218
cibinetidecibinetide
Q27273306
F85496
MS-32078
EX-A6264
GLXC-26513
AKOS040763919

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" This review focusses on the current status of protective pathways mediated by EPO, the safety concerns using high EPO dosage and discusses the discrepancies between pre-clinical and clinical studies."( Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events.
Leuvenink, HG; Ploeg, RJ; van Goor, H; van Rijt, WG, 2014
)
0.4
" ARA290 exerted a dose-response effect by significantly reducing mechanical allodynia up to 20 weeks when compared to vehicle."( ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.
Aarts, L; Brines, M; Cerami, A; Dahan, A; Dunne, A; Niesters, M; Swartjes, M; van Velzen, M, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's36 (85.71)24.3611
2020's6 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.13 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index39.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (9.30%)5.53%
Reviews4 (9.30%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (81.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]